@ chemonave patients with stage IIIB/IV NSCLC received oral vinorelbine ( first cycle @ mg/m ( @ ) , subsequent cycles : @ mg/m ( @ ) in the absence of any hematological toxicity grade @ in cycle @ ) once daily on days @ and @ of each cycle and cisplatin ( @ mg/m ( @ ) i.v. ) on day @ of each cycle ( q@w ) .